Development of a treatment for chronic cough in idiopathic pulmonary fibrosis (IPF)

Challenge: A vast majority of IPF patients (75%) suffer from refractory cough and there is no treatment for this condition. Patara Pharma was founded to address this significant unmet need.
Solution: Patara repurposed a pharmaceutical anti-inflammatory drug for the treatment of this condition. A drug-device combination product was developed with a strong intellectual property (IP) position.
Results: The combination product exhibited excellent PK results with AUC values 5-times (5X) greater than what had been achieved thus far. Phase 2a data showed significant improvement in refractory cough compared to placebo. Patara was acquired by Roivant Sciences on the basis of these positive results.